TheEdgeResearch
Home / Stocks / DPHAY

Dechra Pharmaceuticals PLC (DPHAY)

OTC Healthcare Drug Manufacturers - General
$98.00 ▲ +1.98%
Market Cap
$5.58B
Sector
Healthcare
Industry
Drug Manufacturers - General
Beta
0.75
52-Wk Range
61.61-98.0
CEO
Ian D. Page
Country
GB
Currency
USD

Dechra Pharmaceuticals PLC operates in the Drug Manufacturers - General industry of the Healthcare sector, headquartered in Northwich, GB. The stock last traded at $98.00, up 1.98% on the session, giving a market capitalisation of $5.58B. On trailing twelve-month figures it carries a trailing P/E of -161.08, a net margin of -3.7%. Its beta of 0.75 implies it has historically moved less than the broad market.

Valuation & profitability (TTM)
P/E
-161.08
Price / Sales
5.78
Price / Book
5.81
EV / EBITDA
55.75
Gross margin
56.0%
Operating margin
0.8%
Net margin
-3.7%
Return on equity
Debt / equity
0.67
Current ratio
2.85
Dividend yield
0.3%
Payout ratio
-185.3%
Company profile
Exchange
Other OTC
Employees
2,457
IPO date
2018-02-26
Headquarters
Northwich, GB
About Dechra Pharmaceuticals PLC

Dechra Pharmaceuticals PLC (DPHAY) is dedicated to the development, manufacturing, regulatory approval, marketing, and sale of veterinary medications and related goods specifically for animal health professionals. The company's operations are structured into three key divisions: European Pharmaceuticals, North American Pharmaceuticals, and Pharmaceutical Research and Development. Its extensive product portfolio addresses various animal species: For companion animals like dogs and cats, Dechra offers treatments covering endocrine disorders, dermatological conditions, pain relief, anesthesia, cardiovascular health, and critical care. For livestock, including poultry, pigs, and cattle, the company provides water-soluble antibiotics, avian vaccines, and pain management solutions. Equine offerings primarily focus on lameness and pain management for horses and ponies. Additionally, Dechra supplies specialized nutritional products designed to support cats and dogs with specific therapeutic needs, such as allergies, obesity, and heart or kidney diseases. Beyond its core pharmaceutical activities, the company also distributes veterinary equipment, offers certain financial services, and is involved in the development, regulation, production, and commercialization of crop protection products. Dechra's products reach the market primarily through established networks of wholesalers and distributors. The company's geographical footprint encompasses the United Kingdom, Germany, other European nations, the United States, and various international territories. Dechra Pharmaceuticals PLC was established in 1997 and its corporate headquarters are located in Northwich, United Kingdom.

Comparable companies

Dechra Pharmaceuticals PLC is most often compared with the following Healthcare names:

ABCZFANHGYASPHFCAKFYGALNFHNGZYINVVYIZQVFLYPHFSGIPF
More research on DPHAY
DPHAY technical analysis DPHAY TheEdge Score Compare against peers
Open full interactive analysis & DCF →